tradingkey.logo

Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio

ReutersJun 16, 2025 11:43 AM

- Supernus Pharmaceuticals Inc SUPN.O:

  • SUPERNUS PHARMACEUTICALS TO ACQUIRE SAGE THERAPEUTICS, STRENGTHENING ITS NEUROPSYCHIATRY PRODUCT PORTFOLIO

  • UPFRONT CASH PAYMENT OF $8.50 PER SHARE

  • EXPECTED TO BE SIGNIFICANTLY ACCRETIVE IN 2026 WITH POTENTIAL COST SYNERGIES OF UP TO $200 MILLION ON AN ANNUAL BASIS

  • DEALFOR AN AGGREGATE OF UP TO APPROXIMATELY $795 MILLION OR $12.00 PER SHARE

Further company coverage: SUPN.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI